echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > EHJ and NEJM: Hypertension or associated with an increased risk of death from COVID-19 infection

    EHJ and NEJM: Hypertension or associated with an increased risk of death from COVID-19 infection

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    , June 9, 2020 /PRNewswire/ -- In a study published in the international journalThe European Heart Journal
    , scientists from the West Beijing Hospital and other institutions found that patients withhigh blood pressureare twice as likely to die from COVID-19 infection than those withhigh blood pressure, and patients withblood pressure that does not control blood
    pressure may be at higher risk of dying from COVID-19Photo Source: European HeartIn the paper, researchers analyzed data on 2,866 patients admitted to Wuhan's Vulcan Mountain Hospital between February 5 and March 15, 2020, of whom 850 (29.5%) had a history ofhigh blood pressure, and researcher Professor Li Fei said that 34 (4%) of 850 patients with hypertension had a history of high blood pressureCoVID-19 died, while 22 (1.1%) of 2,027 nonhypertensive patients died from COVID-19, and when adjusted for factors such as age, gender and other medical conditions, the researchers found that patients with hypertension were 2.12 times more likely to die from COVID-19 than nonhypertensive patients11 out of 140 people with high blood pressure who were not treated with medication (7.9%) died from COVID-19, while 23 of the 710 patients who took the drug died (3.2%) after adjusting the mixed factors, the former had a 2.17 times higher risk of death from COVID-19 than the latter; Data from 300 patients were mixed to investigate the mortality rates of patients treated with drugs that target the drug that controls blood pressure by the erythropoietin-angiotensin-aldosterone system (RAAS), including angiotensin conversion enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), and other non-RAAS inhibitors used to treat hypertension, including beta blockers, calcon channels blockers (CCBs) or diuretsresearchers found that the mortality rate was lower for 183 patients treated with RAAS inhibitors compared to 527 patients treated with other drugs, and caution should be taken because the number of patients in the analysis was small and therefore possibly accidental Therefore, people with hypertension need to realize that their risk of dying from COVID-19 increases, and that they should be more careful in this pandemic In addition, 140 patients admitted to hospital with COVID-19 stopped treatment for hypertension for a variety of reasons, which may be directly related to the higher risk of death from COVID-19 infection RAAS inhibitors such as ACE inhibitors or angiotensin blockers may not be associated with an increased risk of death from COVID-19 infection, and in fact these drugs can also have protective effects on patients; In a previous study published in the international journal new England Journal of Medicine
    , researchers found that antihypertensive drugs such as ACE inhibitors or ARBs may not be associated with an increased risk of death in patients who are COVID-19 positive concluded that this was just a retrospective observational study that did not prove a causal link between RAAS inhibitors and COVID-19 death risk, while other limitations included the inability to include all relevant confounding factors, such as electrocardiograms that were not documented in detail, and that researchers were required to conduct forward-looking studies to observe their long-term effects ( original origins: Chao Gao, Yue Cai, Kan Zhang, et al.
    Association of the sgold and anti-gourd treatment with COVID-19 mortality: a retrospectiveal study .
    European Heart Journal (2020) DOI: 10.1093/eurheartj/ehaa433
    Giuseppe Mancia, Federico Rea, Monica Ludergnani, et al.
    Renin -Angiotensin- Aldosterone System Blockers and The Risk of Covid-19
    , New England Journal of Medicine (2020) DOI: 10.1056/NEJMoa2006923
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.